Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDTV7A)

• Drug Name: BV-6 Drug Info
• Synonyms: BV6

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 23657864
  ChEBI ID: CHEBI:47924
  TTD Drug ID: DMDTV7A

Molecule-Related Drug Atlas

Drug(s) Targeting XIAP messenger RNA (XIAP mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASTX660	DMMKW8L	Lymphoma	2A80-2A86	Phase 2	[2]
AEG35156	DM2HRYD	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
EMBELIN	DMFZO4Y	N. A.	N. A.	Terminated	[4]
AZD5582	DMPIHN6	Discovery agent	N.A.	Investigative	[5]
SM-337	DMOSTP9	Discovery agent	N.A.	Investigative	[6]
SM-131	DMP8VO6	Discovery agent	N.A.	Investigative	[7]
SM-122	DMC7YQE	Discovery agent	N.A.	Investigative	[6]
ARPFAQK-FAM	DMU70YP	Discovery agent	N.A.	Investigative	[4]
AVPIAQKSEK-FAM	DMNQ9R4	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Cellular inhibitor of apoptosis 1 (BIRC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT-406	DMVJW0S	Squamous head and neck cell carcinom	2D60.0	Phase 3	[8]
Birinapant	DM6PBUM	Lymphoma	2A80-2A86	Phase 2	[9]
PMID25980951-Compound-6	DMVSW5N	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-27	DMXAH9F	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-43	DMTJRCS	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-1	DMYPT2H	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-44	DMS5896	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-3	DMPSWXU	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-4	DM9RZSH	N. A.	N. A.	Patented	[10]
PMID25980951-Compound-21	DMIE0MR	N. A.	N. A.	Patented	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cellular inhibitor of apoptosis 1 (BIRC2)	TTQ5LRD	BIRC2_HUMAN	Inhibitor	[1]
XIAP messenger RNA (XIAP mRNA)	TTK3WBU	XIAP_HUMAN	Inhibitor	[1]

References

• [1] IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
• [4] Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40.
• [5] Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.
• [6] Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7.
• [7] Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of ca... J Med Chem. 2008 Dec 11;51(23):7352-5.
• [8] Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
• [9] cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
• [10] Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.